Hisamitsu Pharmaceutical Co., Inc.

OTCPK:HTSU.F Stock Report

Market Cap: US$1.9b

Hisamitsu Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Hisamitsu Pharmaceutical's earnings have been declining at an average annual rate of -6.6%, while the Pharmaceuticals industry saw earnings growing at 1.3% annually. Revenues have been growing at an average rate of 0.3% per year. Hisamitsu Pharmaceutical's return on equity is 5.7%, and it has net margins of 10.1%.

Key information

-6.6%

Earnings growth rate

-4.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate0.3%
Return on equity5.7%
Net Margin10.1%
Last Earnings Update31 May 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Hisamitsu Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:HTSU.F Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 May 24145,42014,70859,4888,614
29 Feb 24141,70613,96957,1898,614
30 Nov 23139,27614,33053,3709,785
31 Aug 23135,68813,65552,0159,785
31 May 23134,03314,16051,4459,785
28 Feb 23128,33011,74251,3149,785
30 Nov 22125,41112,96249,58610,613
31 Aug 22121,26111,16049,94310,613
31 May 22118,8258,92749,86310,613
28 Feb 22120,1939,65850,11710,613
30 Nov 21120,3519,74649,98910,766
31 Aug 21120,13510,55949,62510,766
31 May 21117,38911,49948,08210,766
28 Feb 21114,5109,25047,73510,766
30 Nov 20122,7368,99650,81610,504
31 Aug 20130,51714,83951,88510,504
31 May 20136,64116,89452,95110,504
29 Feb 20140,99218,69454,37110,504
30 Nov 19139,91221,29551,01713,032
31 Aug 19137,42517,59451,66413,032
31 May 19139,14217,66553,37813,032
28 Feb 19143,40819,20453,36913,032
30 Nov 18140,89116,60850,62015,076
31 Aug 18143,79118,89149,53515,076
31 May 18145,28818,89749,31615,076
28 Feb 18147,87019,11950,76015,076
30 Nov 17145,74917,89550,79914,378
31 Aug 17144,94120,49549,02714,378
31 May 17143,85319,54049,27314,378
28 Feb 17145,92520,39551,15614,378
30 Nov 16149,29820,80652,19714,965
31 Aug 16153,87117,69456,49714,965
31 May 16160,32518,77859,20914,965
29 Feb 16161,85217,78459,76914,965
30 Nov 15164,08619,62662,66813,718
31 Aug 15162,11918,58664,34413,718
31 May 15158,66718,32164,68513,718
28 Feb 15156,74318,78464,48913,718
30 Nov 14150,44616,64564,06213,924
31 Aug 14150,30517,25063,13813,924
31 May 14151,32617,84162,32513,924
28 Feb 14150,63521,35761,24313,924
30 Nov 13150,54422,97659,71212,662
31 Aug 13148,22223,15656,64012,662

Quality Earnings: HTSU.F has high quality earnings.

Growing Profit Margin: HTSU.F's current net profit margins (10.1%) are lower than last year (10.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HTSU.F's earnings have declined by 6.6% per year over the past 5 years.

Accelerating Growth: HTSU.F's earnings growth over the past year (3.9%) exceeds its 5-year average (-6.6% per year).

Earnings vs Industry: HTSU.F earnings growth over the past year (3.9%) did not outperform the Pharmaceuticals industry 16.6%.


Return on Equity

High ROE: HTSU.F's Return on Equity (5.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/07/20 04:05
End of Day Share Price 2024/04/23 00:00
Earnings2024/05/31
Annual Earnings2024/02/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hisamitsu Pharmaceutical Co., Inc. is covered by 14 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Toshiro YoshinagaAizawa Securities Co. Ltd.
Ritsuo WatanabeBofA Global Research
Hidemaru YamaguchiCitigroup Global Markets Japan Inc.